More Proteomics International Laboratories Ltd. news
Proteomics International Laboratories Ltd.ASX: PIQ

Proteomics joins major health study to target lung disease

Dec 3, 2017 at 10:44 PM EST · Issued by Proteomics International Laboratories Ltd.

Filed with ASX · Dec 3, 2017 at 10:44 PM EST · 3 pages · English

On 6ix: 6ix.com/news/proteomics-joins-major-health-study-to-target-lung-disease

Proteomics International Laboratories Ltd. on 6ix

Earlier from Proteomics International Laboratories

  • PromarkerD predictive diagnostic test to launch in Q1 2018Nov 26, 2017
  • Proteomics partnered consortium to receive $2 millionOct 26, 2017
  • Appendix 4C - September 2017 Quarterly ReportOct 25, 2017
  • Proteomics receives R&D tax incentiveOct 9, 2017
  • PromarkerD predictive test results published - Diabetes CareSep 6, 2017

Later from Proteomics International Laboratories

  • Appendix 4C - December 2017 Quarterly ReportJan 25, 2018
  • PromarkerD diabetic kidney disease patent granted in JapanJan 28, 2018
  • Strategic alliance and investment in CPR Pharma ServicesFeb 1, 2018
  • Proteomics launches PromarkerDMar 6, 2018
  • Proteomics secures underwriting - PIQ Options to raise $3.4mMar 13, 2018
All Proteomics International Laboratories news releases↗

Follow Proteomics International Laboratories into a list and get an email when it puts out news.

Follow Proteomics International Laboratories
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer